Brief: Sellas Life Sciences Group Inc Provides Business Update And Reports First Quarter 2023 Financial Results
11/05/2023 22:38
May 11 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS LIFE SCIENCES GROUP INC - PROVIDES BUSINESS UPDATE
AND
REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
* SELLAS - PHASE 3 REGAL STUDY OF GALINPEPIMUT-S IN PATIENTS
WITH
ACUTE MYELOID LEUKEMIA ON TRACK FOR INTERIM ANALYSIS BY LATE
2023/EARLY 2024
* SELLAS LIFE SCIENCES GROUP INC - QTRLY LOSS PER SHARE
$0.47
Source text for Eikon: ID:
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses